Aller au contenu
Black Friday — 30% OFFLivraison gratuite dès 99 € d’achat
  1. Accueil
  2. Santé hormonale et croissance
  3. CJC-1295 with DAC, 2mg
Santé hormonale

CJC-1295 with DAC, 2mg

CJC-1295 with DAC is a synthetic modified peptide compound studied for its interactions with growth hormone-releasing hormone (GHRH) receptor pathways in experimental models.

Conditionnement: CJC-1295 with DAC, 2mg.

Sélectionnez le dosage et le conditionnement souhaités.

Conditionnement illustratif généré par IA.

Conditionnement
Le prix initial était : 479,50 €.Le prix actuel est : 335,65 €.

Disponible sur demande en France

Demander à un conseiller
Un conseiller vous contacte et la pharmacie partenaire vérifie si et comment la demande peut aboutir. Une ordonnance valide, ou une évaluation par un service de télémédecine autorisé, peut être nécessaire.
  • Pharmacie partenaire
  • Accompagnement personnalisé
  • Livraison discrète
  • Conditionnement
    CJC-1295 with DAC, 2mg

Expédition et livraison

  • Expédition habituellement sous 24 heures après confirmation du paiement.
  • USPS Regular Shipping · 11,95 € · Env. 3–5 jours ouvrés
  • FedEx 2 Days Delivery · 28,99 € · Env. 2 jours ouvrés
  • FedEx Overnight Delivery · 40,99 € · Env. 1 jour ouvré

Réservé à la recherche en laboratoire.

Ne pas utiliser chez l’être humain ou l’animal.

Composition et détails du produit

Présentation

CJC-1295 with DAC is a synthetic modified peptide compound studied for its interactions with growth hormone-releasing hormone (GHRH) receptor pathways in experimental models.

The Drug Affinity Complex (DAC) modification — a maleimidopropionyl-lysine moiety at the C-terminus — is studied for its capacity to reversibly bind albumin in experimental systems, producing extended stability compared to the unmodified CJC-1295 variant.

The compound is designed with a 30-amino acid sequence structure incorporating four amino acid substitutions that confer enhanced protease resistance relative to native GHRH(1-29). Research applications include GHRH receptor pathway studies, growth hormone secretagogue signalling research, and comparative DAC-modified versus unmodified peptide pharmacology.

  • High Purity – 99% Purity Guaranteed
  • Independently Lab Tested
  • Research Grade Quality
  • For Laboratory Research Use Only

Propriétés

Chemical Formula C165H269N47O46
Synonyms CJC1295 With DAC, 446262-90-4
Molar Mass 3647.2 g/mol
CAS Number 446262-90-4
PubChem CID 91971820
Formats disponibles Vial · KIT (10 vials)
Shelf Life 36 months

Recherche

CJC-1295 with DAC is a synthetic 30-amino acid GHRH analogue studied for selective receptor affinity and extended stability in laboratory research models. The compound incorporates four amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) that confer enhanced protease resistance relative to native GHRH(1-29), and a Drug Affinity Complex (DAC) modification at the C-terminus studied for its capacity to reversibly bind albumin in experimental systems, producing significantly extended peptide stability relative to the non-DAC CJC-1295 variant. Laboratory research has examined its growth hormone secretagogue signalling properties — including proposed modulation of pituitary GHRH receptor pathways and downstream IGF-1 axis signalling — in cell-based and in vivo experimental models. Comparative research protocols frequently pair CJC-1295 with DAC against the non-DAC variant to characterise the contribution of the albumin-binding modification to receptor engagement duration and downstream signalling profiles. Independently third-party HPLC-tested; COA available per batch.

FAQ

What is the Drug Affinity Complex (DAC) modification and how does it affect CJC-1295’s stability in research models?

The DAC modification in CJC-1295 is a maleimidopropionyl-lysine moiety incorporated at the C-terminus of the peptide sequence, studied for its capacity to reversibly bind cysteine-34 of albumin in experimental systems. This albumin-binding interaction is studied for its role in significantly extending the peptide’s stability in biological research models relative to the non-DAC CJC-1295 variant, making the DAC form a standard research tool in protocols requiring sustained receptor pathway engagement over extended experimental timelines.

How do the four amino acid substitutions in CJC-1295 differ from native GHRH(1-29)?

CJC-1295 incorporates D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27 relative to native GHRH(1-29), substitutions studied for their capacity to confer enhanced resistance to proteolytic degradation while preserving GHRH receptor binding affinity. These modifications are examined in comparative structure-activity research contrasting CJC-1295’s stability and receptor binding profile against native GHRH(1-29) and other GHRH analogues.

What advantages does the 10-vial KIT format provide for extended research programs?

The 10-vial KIT format is particularly useful for longitudinal investigations, repeated-dose studies, multi-arm experimental designs, pharmacokinetic research, and chronic pathway-signaling programs requiring consistent compound availability across multiple study phases.

Individually sealed vials allow compound to remain lyophilized until needed, supporting stability throughout extended research timelines. The use of matched-batch material across all ten vials also helps minimize variability between experimental sessions, making the KIT format well suited to long-duration receptor-signaling and comparative pharmacology studies.

Le prix initial était : 479,50 €.Le prix actuel est : 335,65 €.